Lebrikizumab in moderate-to-severe asthma: pooled data from two randomised placebo-controlled studies

  title={Lebrikizumab in moderate-to-severe asthma: pooled data from two randomised placebo-controlled studies},
  author={Nicola Alexander Hanania and Michael J Noonan and Jonathan Corren and Phillip E. Korenblat and Yanan Zheng and Saloumeh Kadkhodayan Fischer and Melissa Cheu and Wendy S. Putnam and Elaine Murray and Heleen Scheerens and C{\'e}cile T. J. Holweg and Romeo Maciuca and Sarah Gray and Ramona Doyle and Dana E McClintock and Julie Olsson and John V. G. Matthews and Karl Yen},
INTRODUCTION In a subset of patients with asthma, standard-of-care treatment does not achieve disease control, highlighting the need for novel therapeutic approaches. Lebrikizumab is a humanised, monoclonal antibody that binds to and blocks interleukin-13 activity. METHODS LUTE and VERSE were replicate, randomised, double-blind, placebo-controlled studies, evaluating multiple doses of lebrikizumab in patients with uncontrolled asthma despite the use of medium-to-high-dose inhaled… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 27 times. VIEW TWEETS


Publications citing this paper.
Showing 1-10 of 91 extracted citations

Inflammatory and Noninflammatory Itch: Implications in Pathophysiology-Directed Treatments

International journal of molecular sciences • 2017
View 9 Excerpts
Highly Influenced

Targeted Therapy for Severe Asthma: Identifying the Right Patients

Molecular Diagnosis & Therapy • 2016
View 4 Excerpts
Highly Influenced


Publications referenced by this paper.
Showing 1-10 of 24 references

The effects of lebrikizumab in patients with mild asthma following whole lung allergen challenge

Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology • 2014

Lebrikizumab treatment reduces serum periostin levels in asthma patients with elevated baseline levels of periostin [ abstract ]

H Scheerens, J Arron, D Choy
Am J Respir Crit Care Med • 2012

Periostin is a systemic biomarker of eosinophilic airway in fl ammation in asthma

G Jia, RW Erickson, DF Choy
J Allergy Clin Immunol • 2012

Lebrikizumab treatment in adults with asthma.

The New England journal of medicine • 2011

Similar Papers

Loading similar papers…